Literature DB >> 35083711

Immunoreactivity of Brugia malayi Calreticulin and Its Domains with Sera of Different Categories of Bancroftian Filarial Patients.

Sunita Yadav1, Smita Gupta1, Mohd Saeed2,3, Huma Mustafa2,4, Jitendra Kumar Saxena1, Puvvada Kalpana Murthy5,6.   

Abstract

PURPOSE: We identified calreticulin in human filaria Brugia malayi (BmCRT) that shares 97% homology with Wuchereria bancrofti calreticulin (WbCRT), but only 56% with human calreticulin. We found that BmCRT binds C1q and prevents complement-mediated parasite death; immunization with BmCRT leads to parasite death in a rodent model of the infection. BmCRT could, therefore, be a potential vaccine candidate. In the present study, we determined the levels of BmCRT-reactive IgG and its isotype in bancroftian filarial subjects.
METHODS: Recombinant BmCRT (rBmCRT) was prepared, and the sera of endemic normal subjects (EN), microfilaraemics (Mf+) and chronic amicrofilaraemics (ChMf-) from a bancroftian filaria-endemic area and normal subjects from filaria-non-endemic area (NEN) were probed for IgG and its isotypes reacting with rBmCRT and its domains rN, rP and rC.
RESULTS: rBmCRT and its rN domain-reactive IgG levels were high in EN and Mf+ groups; rC domain and rP domain showed moderate and very little reactivity, respectively. NEN sera were non-reactive. Moderate levels of rBmCRT-reactive IgG1, IgG3 and IgG4 in EN and Mf+ groups and low levels of IgG2 in Mf+ were found; IgG1 and IgG3 reactivity was found for rBmCRT and its rN domain only, while IgG4 reactivity was moderate for rN domain and low for rP and rC domains. While IgG reactivity was seen in all the endemic subjects, IgG isotype reactivity was found mostly in EN and Mf+ subjects.
CONCLUSIONS: Moderate levels of rBmCRT (and its rN domain)-reactive IgG and its isotypes are present in bancroftian subjects. Preponderance of IgG1 and IgG3 isotypes which bind and activate complement has relevance to vaccine potential of BmCRT.
© 2021. The Author(s) under exclusive licence to Witold Stefański Institute of Parasitology, Polish Academy of Sciences.

Entities:  

Keywords:  BmCRT and its domains; Brugia malayi; Calreticulin; Filarial patients; IgG isotypes

Mesh:

Substances:

Year:  2022        PMID: 35083711     DOI: 10.1007/s11686-021-00504-2

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.440


  32 in total

Review 1.  Immunomodulation by filarial nematodes.

Authors:  A Hoerauf; J Satoguina; M Saeftel; S Specht
Journal:  Parasite Immunol       Date:  2005 Oct-Nov       Impact factor: 2.280

Review 2.  Molecular basis of worm-induced immunomodulation.

Authors:  W Harnett; M M Harnett
Journal:  Parasite Immunol       Date:  2006-10       Impact factor: 2.280

3.  Recombinant Calponin of human filariid Brugia malayi: Secondary structure and immunoprophylactic potential.

Authors:  Shiv K Verma; Ashish Arora; P Kalpana Murthy
Journal:  Vaccine       Date:  2017-08-05       Impact factor: 3.641

Review 4.  Lymphatic filariasis in India: epidemiology and control measures.

Authors:  Khk Raju; P Jambulingam; S Sabesan; P Vanamail
Journal:  J Postgrad Med       Date:  2010 Jul-Sep       Impact factor: 1.476

5.  Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift.

Authors:  A Doetze; J Satoguina; G Burchard; T Rau; C Löliger; B Fleischer; A Hoerauf
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

6.  Troponin 1 of human filarial parasite Brugia malayi: cDNA cloning, expression, purification, and its immunoprophylactic potential.

Authors:  Vikas Kushwaha; Prachi Tewari; Payal Mandal; Anurag Tripathi; P Kalpana Murthy
Journal:  Parasitol Res       Date:  2019-05-04       Impact factor: 2.289

7.  Disorganized muscle protein-1 (DIM-1) of filarial parasite Brugia malayi: cDNA cloning, expression, purification, structural modeling and its potential as vaccine candidate for human filarial infection.

Authors:  Vikas Kushwaha; Vikash Kumar; Shiv K Verma; Rolee Sharma; M I Siddiqi; P K Murthy
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

Review 8.  Advances in Vaccine Development for Human Lymphatic Filariasis.

Authors:  Ramaswamy Kalyanasundaram; Vishal Khatri; Nikhil Chauhan
Journal:  Trends Parasitol       Date:  2019-12-19

9.  Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka.

Authors:  Ramakrishna U Rao; Sandhya D Samarasekera; Kumara C Nagodavithana; Tharanga D M Dassanayaka; Manjula W Punchihewa; Udaya S B Ranasinghe; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2017-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.